Compare GSK plc (GSK) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lennar Corporation — how do they compare? GSK plc trades at $52.74 (market cap $101.34B), while Lennar Corporation trades at $86.89 (market cap $20.49B). The key difference: GSK plc is far larger — about 4.9× Lennar Corporation's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | LEN | |
|---|---|---|
Market Cap | $101.34B | $20.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $142.40 |
52-Week Low | $36.20 | $82.30 |
Enterprise Value | $121.95B | $24.37B |
Dividend Yield | 3.49% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Lennar (LEN) trades at $83.71, showing modest daily gains but facing significant technical headwinds with a bearish moving average signal and recent earnings misses. The stock appears fundamentally undervalued with a P/E of 13.37 and P/B of 0.95, though profitability metrics have compressed with net income margin declining to 4.93% in 2025. Recent corporate actions include consistent $0.50 quarterly dividends, while news highlights the company's strategic shift toward volume over price amid housing affordability challenges.
The outlook presents a value opportunity with attractive valuation multiples, but execution risks remain high as Lennar navigates margin pressure from lower home prices and elevated mortgage rates. Analyst consensus leans bullish with a $84.78 price target, though recent earnings disappointments and bearish technical indicators suggest near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
